The new branding brings all the agency brands under one cohesive identity with the shared purpose of transforming science into value to make a positive impact on patient lives.
Yesterday the company terminated the development of its investigational bispecific T-cell engager AMG 794, which it had been studying in a Phase I trial for several solid tumors including non-small cell lung cancer and epithelial ovarian cancer.
The regulator added atopic dermatitis to the label of Arcutis Biotherapeutics’ topical PDE4 inhibitor Zoryve for the treatment of patients six years of age and older.
Interius BioTherapeutics has received approval from Australia’s Human Research Ethics Committee to begin the first-in-human trial of an investigational in vivo CAR-T therapy designed to treat B-cell malignancies.
Danish drugmaker Novo Nordisk has signed a deal with Indonesia’s state-owned pharmaceutical company Bio Farma to package insulin to combat diabetes in the Southeast Asian country, a Bio Farma senior official stated.
Only one in four U.S. patients prescribed Novo Nordisk’s Wegovy or Ozempic for weight loss were still taking the popular medications two years later, according to an analysis of U.S. pharmacy claims provided to Reuters that also showed a steady decline in use over time.